Profound Med Corp Stock Price, News & Analysis

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will announce its third quarter 2021 financial results on November 4, 2021, after market close. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and business developments. Profound specializes in customizable, incision-free therapies for diseased tissue, including the TULSA-PRO® system for prostate ablation and Sonalleve® for uterine fibroids. Both technologies have received necessary regulatory approvals, enhancing their market potential.

Profound Medical Corp. (NASDAQ: PROF) has announced its participation in two upcoming investor conferences in September 2021. On September 15, the company will hold one-on-one meetings at Lake Street’s 5th Annual Best Ideas Growth Conference. Following that, on September 30 at 8:00 a.m. ET, Profound will present at the Cantor Virtual Global Healthcare Conference, which will be broadcast live on its website. Profound focuses on developing incision-free therapies, like TULSA-PRO^® for prostate cancer and Sonalleve^® for uterine fibroids.

Profound Medical Corp. (NASDAQ: PROF) reported a strong second quarter for 2021, with revenue of approximately $2.6 million, a 156% increase year-over-year. The growth was driven by a 145% rise in recurring revenues. Despite increased operational expenses totaling $7.6 million, net loss slightly widened to about $7.0 million, or $0.35 per share. The company maintains a solid liquidity position with $73.8 million in cash. CEO Arun Menawat remains optimistic about future performance, despite ongoing COVID-19 challenges in certain markets.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. The event will feature one-on-one virtual investor meetings, with no webcast available.

Profound specializes in incision-free therapies for diseased tissue, including the TULSA-PRO^® for prostate ablation and Sonalleve^® for uterine fibroids. Both technologies have received various regulatory approvals, enhancing their market potential.

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call will follow at 4:30 p.m. ET for management to discuss the results and business developments. Profound is known for its innovative medical devices, including the TULSA-PRO^® for prostate ablation and Sonalleve^® for uterine fibroid treatment. The company has received CE marking and FDA clearance for its technologies, showing strong regulatory support for its offerings.

Profound Medical Corp. (NASDAQ: PROF) announced participation in two investor conferences this June. The Jefferies Virtual Healthcare Conference will feature a fireside chat on June 1, 2021, at 10:00 a.m. ET, while the Raymond James Human Health Innovations Conference is set for June 22, 2021, at the same time. These events will be streamed live on the Company’s website. Profound specializes in customizable, incision-free therapies for ablation, including TULSA-PRO® for prostate treatment and Sonalleve® for uterine fibroids.

Profound Medical Corp. held its Annual Meeting of Shareholders on May 19, 2021, with 58.044% of shares represented. All proposed matters were approved, including the election of seven directors, receiving over 97% support. PricewaterhouseCoopers LLP was appointed as auditors until the next annual meeting. Notably, Rashed Dewan was appointed as Chief Accounting Officer, while Aaron Davidson transitioned to SVP Corporate Development, no longer serving as CFO. Profound specializes in incision-free therapies, notably the TULSA-PRO® and Sonalleve® technologies for prostate and uterine treatments.

Profound Medical Corp. (NASDAQ:PROF) reported its Q1 2021 financial results with revenue of approximately $711,000, a decline of 39% from $1.2 million in Q1 2020. This revenue includes $234,000 from a capital equipment sale and $477,000 from recurring revenue. Total operating expenses rose to $6.8 million, up 28% year-over-year. The net loss was around $7.5 million, or $0.37 per share. Despite early pandemic impacts, the company anticipates potential revenue recovery throughout 2021, with cash reserves at $78.5 million.

Profound Medical Corp. (NASDAQ:PROF) has announced a multi-site imaging center agreement with Akumin Inc. to integrate TULSA-PRO® systems at up to 10 Akumin centers, focusing on men’s health. The partnership aims to enhance prostate care services, particularly in Florida. The first TULSA-PRO® site is expected to be operational in Q4 2021. TULSA-PRO® offers customizable, incision-free treatments for prostate diseases, enhancing patient quality of life.